BioMarin Pharmaceuticals (BMRN)

• Market cap: $12.7B
• 1 day: 0.80%
• 5 days: 0.51%
• 1 month: -5.14%
• 3 months: -26.74%
• 6 months: -17.19%
• Year to date: -32.01%
• 1 year: -20.06%
• 5 years: -12.45%
• 10 years: -24.18%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

1% more funds holding

Funds holding: 540 [Q1] → 548 (+8) [Q2]

10% more first-time investments, than exits

New positions opened: 90 | Existing positions closed: 82

0% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]

0.34% less ownership

Funds ownership: 98.01% [Q1] → 97.67% (-0.34%) [Q2]

1% less repeat investments, than reductions

Existing positions increased: 189 | Existing positions reduced: 190

8% less call options, than puts

Call options by funds: $153M | Put options by funds: $166M

5% less capital invested

Capital invested by funds: $16.2B [Q1] → $15.3B (-$885M) [Q2]

Research analyst outlook

28 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $65 2% downside
• Avg. target: $96 44% upside
• High target: $122 83% upside

28 analyst ratings

• positive: 18 64%
• neutral: 10 36%
• negative: 0 0%

Citigroup David Lebovitz 100% 1-year accuracy 8 / 8 met price target	22% upside $81	Neutral Maintained	30 Oct 2024
Canaccord Genuity Whitney Ijem 37% 1-year accuracy 13 / 35 met price target	26% upside $84	Hold Maintained	30 Oct 2024
Cantor Fitzgerald Olivia Brayer 77% 1-year accuracy 20 / 26 met price target	35% upside $90	Overweight Maintained	30 Oct 2024
JP Morgan Jessica Fye 65% 1-year accuracy 31 / 48 met price target	64% upside $109	Overweight Maintained	30 Oct 2024
RBC Capital Luca Issi 43% 1-year accuracy 23 / 53 met price target	20% upside $80	Sector Perform Reiterated	30 Oct 2024